- BGI Publishes Largest Ever Genomic Study of Chinese Population Discoveries in more than 140,000 Genomes throughout China
- BGI, NOAA Fisheries, and The Nature Conservancy Announce Partnership to Help Endangered Orcas
- BGI Signs Memorandum of Understanding with The University of Michigan
- China National GeneBank Signs a Colleboration Agreement with Queensland University on Scientific Research
- Establishment of the first Macaca fascicularis gut microbiome gene catalog
- Establishing the first gene catalogue of Sprague-Dawley rat gut metagenome based on the BGISEQ-500 platform
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Meet The Chinese Company That Wants To Be The Intel Of Personalized Medicine
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
Tel: +86-755-36307212Email: firstname.lastname@example.org
September 7th, 2017, Hong Kong, China - Global genomics company, BGI, today announced that it has obtained Clinical Laboratory Improvement Amendments (CLIA) certificate of registration for its Hong Kong based laboratory.
BGI said that the CLIA-certificate of registration is an important step in expanding its offerings to include clinical sequencing services for analysis of specific diseases including cancer and mendelian diseases. In addition, it will provide a stronger footing for genomics-based clinical trial testing as part of BGI’s CRO pharma solutions that support drug discovery and development for its global biopharmaceutical clients.
‘BGI's objective is to offer the broadest array of high quality clinical diagnostics as well as solutions for more efficient research and drug discovery’ Liu Na, Vice President of BGI Genomics, said in a statement.
BGI's existing services portfolio includes a wide variety of sequencing and analytical and bioinformatics services for DNA and RNA as well as a broad genetic screening portfolio covering reproductive health and oncology. BGI’s Hong Kong laboratory was established in 2010. It received accreditation by College of American Pathology (CAP) in 2013, and currently serves as BGI’s largest sequencing and logistics center for its international customers.
‘We are excited about the addition of the CLIA-certificate of registration at our Hong Kong laboratory’ added Li Ning, Chief Development Officer of BGI Genomics. ‘As well as demonstrating that we are committed to the highest operational and quality standards, this certification is also an important milestone in realizing our vision to offer precision medicine to the global market to benefit all patients, wherever they are.’